International Stem Cell Corporation
corporate_fare Company Profile
International Stem Cell Corporation (OTC:ISCO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 8 items for ISCO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 8/10. Across its 8 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for ISCO spans 10-Q, 8-K, PRE 14C, DEF 14A.
Recent high-impact activity:
- ISCO 10-Q: Going-Concern Doubt Cleared After $25.6M LCT Sale; $2.4M Executive Bonus Disclosed
- ISCO Completes $25.25M Sale of Lifeline Cell Technology, Books $19.3M After-Tax Gain
- Q2 Net Loss Widens, Going Concern Warning Issued Amidst Major Subsidiary Divestiture
- ISCO to Sell Core Subsidiary for $25M, Transforming into a Micro-Cap Biotech with $22M in Cash
- International Stem Cell Corp to Sell Lifeline Cell Technology for $25M, Transforming Cash Position
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 48 shares in ISCO as of the October 30, 2026 settlement, unchanged from the prior period — about 1.0 days to cover at its recent average daily volume. On November 19, 2026, 4.3% of ISCO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.